Drug Trial Radar · NCT00241670
Fluorescence-guided Resection of Malignant Gliomas With 5-Aminolevulinic Acid
Last checked: Nov 20, 2026Latest source record: Apr 26, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
415
Actual
Start
Oct 1999
Primary completion
Jul 2004
Sponsor
- Lead sponsor
- medac GmbHIndustry
- Sponsor type
- Industry
- First posted
- Oct 19, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Diagnostic
- Who can join
- All sexes, from 18 years, up to 72 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of the study "Fluorescence-guided resection of malignant gliomas with 5-Aminolevulinic acid (5-ALA) vs. conventional resection" is to determine how accurately contrast agent-accumulating tumour can be removed by primary surgery and to assess the clinical usefulness of this method.
Conditions
- Brain Cancer
- Brain Tumors
- Cancer of Brain
- Primary Brain Tumors
- Brain Tumor, Primary
Interventions
5-aminolevulinic acid (5-ALA)Drug
1.5 grams 5-ALA dissolved in 50 ml water, single dose, orally, 2-4 hours prior to surgery
Primary outcomes
What the sponsor says the trial is designed to measure.
- 1. Percentage of patients with a histologically confirmed malignant glioma (grade III or IV -WHO) without definite residual contrast agent-accumulating tumour in the early post-operative control MRI (within 72 hours of the operation).Time frame: Within 72 hours after surgery
- 2. Progression-free survival 6 months after primary surgical treatment of a malignant gli-oma in patients with histologically confirmed malignant glioma (grade III or IV -WHO).Time frame: Within 6 month after surgery
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.